Latest Quinazolines Stories
- Boehringer Ingelheim obtains exclusive global rights for development and commercialization of CureVac's investigational therapeutic cancer vaccine CV9202 INGELHEIM and TUBINGEN, Germany,
HILDEN, Germany and LONDON, July 28, 2014 /PRNewswire/ -- - Collaboration aims to create and commercialize companion diagnostic using genomic data
LONDON, June 10, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:
- 7 total abstracts accepted for afatinib and other compounds from the company's oncology research program RIDGEFIELD, Conn., May 30, 2014 /PRNewswire/ -- Boehringer Ingelheim today announced
Oncoprex Combined with Tarceva for Patients With and Without EGFR Mutations AUSTIN, Texas, May 20, 2014 /PRNewswire/ -- Genprex,
-- Results from two Phase III studies (LUX-Lung 3 and LUX-Lung 6) add to the body of evidence supporting the importance of first-line treatment with afatinib in patients whose tumors express the EGFR
SAN DIEGO, May 14, 2014 /PRNewswire/ -- Aethlon Medical, Inc. (OTCQB: AEMD), today released the following note authored by its Chairman and CEO, Jim Joyce.
The Majority of Non-Prescribers Anticipate Prescribing Gilotrif Within the Next Three Months, According to Findings from Decision Resources Group BURLINGTON, Mass., April 24, 2014 /PRNewswire/
RIDGEFIELD, Conn. and INDIANAPOLIS, April 14, 2014 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company (Lilly; NYSE: LLY) today announced the U.S.
- Monstrous in size or character; huge; prodigious; monstrously perverse, savage, cruel, etc.